Of note, enhanced phosphorylation of AKT was demonstrated by the treatment of breast and prostate cancer cell lines with capivasertib as a consequence of the protein being held in a hyperphosphorylated but catalytically inactive form following compound binding [36]. Here, AKT1 is linked to prostate cancer.